Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency

Inclusion Criteria: * Completed participation in trial F13CD-3760 (NCT01230021) Exclusion Criteria: * Known or suspected hypersensitivity to trial product or related products * Known history of development of inhibitors against FXIII (factor XIII) * Hereditary or acquired coagulation disorder other than FXIII congenital deficiency * Platelet count (thrombocytes) less than 50X10e9 / L * Previous history of autoimmune disorder involving autoantibodies e.g., systemic lupus erythematosus * Previous history of arterial or venous thromboembolic events e.g., cerebrovascular accident or deep vein thrombosis * Any disease or condition which, judged by the trial physician, could imply a potential hazard to the subject, interfere with the trial participation or trial outcome including renal and/or liver dysfunction